Serum matrix metalloproteinase-2,9 activity, galectin-3 and systemic inflammation in patients with postinfarction heart failure with preserved ejection fraction.

Authors

  • O. Kuryata
  • A. Zabida
  • O. Sirenko

DOI:

https://doi.org/10.26641/2307-0404.2018.1(part1).127244

Keywords:

postinfarction chronic heart failure, metalloproteinase, galectin-3

Abstract

The available data suggest that heart failure (HF) after myocardial infarction (MI) is a very frequent event. Recent meta-analysis showed that restrictive mitral filling pattern, the most severe form of diastolic dysfunction, was presented in approximately 10% of the patients with preserved ejection fraction. In addition, restrictive pattern was associated with poor outcome. However, the true prevalence and relevance of diastolic dysfunction after MI remains to be elucidated. Objective: study was designed to evaluate the serum level of MMP-2,9, galactin-3 and C-reactive protein (C-RP) in postinfarction heart failure with preserved ejection fraction (HFpEF) patients. Methods: We divided all included patients into two main groups: 1st group – 20 patients with HFpEF and history of myocardial infarction. 2nd group – 18 patients with HFpEF and stable angina. Standard laboratory blood tests for erythrocyte sedimentation rate (ESR), C-RP, haematological parameters, lipid profile, glucose, renal and liver function tests were performed and calculated body mass index (BMI) for all patients. MMP activity assay and galectin-3 serum level was detected for all patients. Results: It was established significant differences between study groups in MMP-2, MMP-9 levels. Particularly, patients with HFpEF with MI in anamnesis had significantly higher MMP-2, MMP-9 levels on 21.8% and 20.7% respectively. The C-RP and leucocytes levels were significantly higher in 1st group pts. Significant differences in MMP-2, MMP-9 were established in 1st group patients in different age groups (p<0.05) (tab. 3). The MMP 2 level was positively correlated with MMP 9 level (R=0.73, p<0.05), the MMP 9 level – with age (R=0.68, p<0.05). There were no significant differences between galectin-3 level in study group. But we estimated significant differences in galectin-3 level between 1st and 2nd subgroups (p<0.05). Conclusion: Serum MMP-2, MMP-9, CRP and galactin-3 were significantly increased in pts with postinfarction heart failure with preserved ejection fraction compare to pts without myocardial infarction in anamnesis.

Author Biographies

O. Kuryata

SE «Dnipropetrovsk Medical Academy of Health Ministry of Ukraine»
Department of internal medicine 2
V. Vernadskiy str., 9, Dnipro, 49005, Ukraine

A. Zabida

SE «Dnipropetrovsk Medical Academy of Health Ministry of Ukraine»
Department of internal medicine 2
V. Vernadskiy str., 9, Dnipro, 49005, Ukraine

O. Sirenko

SE «Dnipropetrovsk Medical Academy of Health Ministry of Ukraine»
Department of internal medicine 2
V. Vernadskiy str., 9, Dnipro, 49005, Ukraine

References

Kuryata OV, Sirenko O. [Daily Blood Pressure, lipid profile of blood in patients with arterial hypertension in combination with rheumatoid arthritis and efficacy of atorvastatin]. Simeyna medytsyna. 2015;3 (59):155-9. Ukrainian. doi: 10.22141/2224-1485.6.50.2016.89771

Kuryata OV, Zabida A, Chvora DL. [Risk factors, conditions of cardiohemodynamics and renal function in patients with chronic heart failure and myocardial in­farc­tion in anamnesis]. Medicni perspektivi. 2017;ХХІІ(3):25-32. Ukrainian. https://doi.org/10.26641/2307-0404.2017.3.111914

Kuryata AV, Lysunets TK, Noda OYu. [The ef­fectiveness of cocarina in complex therapy in patients with systemic connective tissue diseases with myocardial damage and manifestations of heart failure]. Mezhdu­narodnyy meditsinskiy zhurnal. 2012;2:44-49. Russian.

Kawamura N, Kubota T, Kawano S, et al. Bloc­kade of NF-κB improves cardiac function and survival without affecting inflammation in TNF-α-induced cardio­myopathy. Cardiovasc. Res. 2005;66:520-9.

Ponikowski P, et al. 2016 ESC Guidelines for the diagnosis and treatment The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC) Developed in collaboration with the Heart Failure Association (HFA) of the ESC. European Heart Journal. 2016;37(27):2129-200. doi: 10.1093/eurheartj/ehs104

Weir RA, Petrie CJ, Murphy CA, et al. Galectin-3 and cardiac function in survivors of acute myocardial infarction. Circ. Heart Fail. 2013;492-8. doi: 10.1161/CIRCHEARTFAILURE.112.000146

de Boer RA, Voors AA, Muntendam P, et al. Ga­lectin-3: a novel mediator of heart failure development and progression. European Journal of Heart Failure. 2009;11(9):811-7. doi: 10.1093/eurjhf/hfp097.

Saksida T, Nikolic I, Vujicic M, et al. Galectin-3 deficiency protects pancreatic islet cells from cytokine-triggered apoptosis in vitro. J Cell Physiol. 2013;228:1568-76. doi: 10.1002/jcp.24318

Gheorghiade M, Fonarow GC. Management of post-myocardial infarction patients with left ventricular systolic dysfunction. Am. J. Med. 2007;120:109-20. doi: 10.1016/j.amjmed.2005.08.010

Møller JE, Whalley GA, Dini FL, et al. Inde­pendent prognostic importance of a restrictive left ven­tricular filling pattern after myocardial infarction: an individual patient me­ta-analysis: Meta-Analysis Research Group in Echocar­dio­graphy acute myocardial infarction. Circulation. 2008;117:2591-8. doi: 10.1161/CIRCULATIONAHA.107.­738625. Epub 2008 May 12.

Sundararaj KP, Samuvel DJ, Sanders JJ, et al. Interleukin-6 released from fibroblasts is essential for upregulation of matrix metalloproteinase-1 expression by u937 macrophages in coculture-crosstalking between fibroblasts and u937 macrophages exposed to high glu­cose. J. Biol. Chem. 2009;284:13714-24.

Mukherjee R, Brinsa TA, Dowdy KB, et al. Myo­cardial infarct expansion and matrix metalloproteinase inhibition. Circulation. 2003;107(4):618-25.

Savarese G, Trimarco B, Dellegrottaglie S, et al. Natriuretic peptide-guided therapy in chronic heart failure: a meta-analysis of 2,686 patients in 12 ran­domized trials. PLoS ONE. 2013;8(3):e58287. doi: 10.1371/journal.pone.0058287. Epub 2013 Mar 5.

Zile MR, De Santis SM, Baicu CF, et al. Plasma galectin- 3 levels in patinets with structural and clinical manifestation of hypertensive heart disease: relationship to determination of matrix composition. Circulation. 2010;122:A12433.

Wilson EM, Moainie SL, Baskin JM, et al. Region- and type-specific induction of matrix me­talloproteinases in post-myocardial infarction remodelling. Circulation. 2003;107(22):2857-63. doi: 10.1161/01.CIR.0000068375.40887.FA

Tsai TH, Sung PH, Chang LT, et al. Value and level of galectin-3 inacute myocardial infarction patients undergoing primary percutaneous coronary intervention. J. Atheroscler. Thromb. 2012;19:1073-82.

Xie Z, Singh M, Singh K. Differential regulation of matrix metalloproteinase-2 and -9 expression and activity in adult rat cardiac fibroblasts in response to interleukin-1β. J. Biol. Chem. 2004;279:39513-9.

Downloads

How to Cite

1.
Kuryata O, Zabida A, Sirenko O. Serum matrix metalloproteinase-2,9 activity, galectin-3 and systemic inflammation in patients with postinfarction heart failure with preserved ejection fraction. Med. perspekt. [Internet]. 2018Apr.24 [cited 2024Jun.24];23(1(part1):89-95. Available from: https://journals.uran.ua/index.php/2307-0404/article/view/127244

Issue

Section

CLINICAL MEDICINE